Challenges and opportunities in insomnia disorder
| Autor: | Jacquelyn W Chou, Timothy Juday, Anupam B. Jena, Rifat Tuly, Paul P Doghramji, Meaghan Roach |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Health Knowledge Attitudes Practice medicine.medical_specialty business.industry General Neuroscience General Medicine Sleep in non-human animals Health Services Accessibility 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Cost of Illness Sleep Initiation and Maintenance Disorders Insomnia medicine Humans medicine.symptom Psychiatry business 030217 neurology & neurosurgery |
| Zdroj: | International Journal of Neuroscience. 131:1058-1065 |
| ISSN: | 1543-5245 0020-7454 |
| DOI: | 10.1080/00207454.2020.1773460 |
| Popis: | Insomnia disorder is a prevalent, often unrecognized condition that affects millions. This clinical disorder is characterized by difficulty initiating or maintaining sleep over a sustained period. In fact, insomnia disorder affects much more than sleep; it increases the risk of developing serious medical and psychiatric comorbidities and can exacerbate existing conditions. The association between insomnia disorder and serious medical and psychiatric comorbidities are complex and directionality is not yet fully understood. There remain gaps in the treatment landscape for insomnia disorder.We performed a narrative review of the published literature to identify challenges, unmet needs, and burden associated with insomnia disorder.In this article, we describe the substantial burden that insomnia disorder poses on patients, the healthcare system, and society in the US. This article explores the factors attributable to this burden including limited provider knowledge, inadequate treatment options, and unknown long-term impacts of off-label treatments.Several recommendations are proposed to address these challenges and improve patient outcomes through efforts to: (1) establish the societal value of treatment; (2) improve the clinical understanding of insomnia disorder; and (3) prioritize development of and access to effective treatments that do not pose addiction potential or tolerability issues. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|